G.d. Searle & Company

Pfizer Corporation

Albert A Jaxa-Chamiec

George J Ellames

Roger M Upton

Simon F Campbell

David A Roberts

Kevin Robert Lawson

Peter L Myers

This disclosure relates to a compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 and R.sup.2 are independently selected from the class consisting of hydrogen, halo, C.sub.1 -C.sub.6 alkyl, and C.sub.1 -C.sub.6 alkoxy;

Substituted 1H-pyrimido[1,2-a-]-pyrido[3,4-e]pyrazine 6 oxides

This disclosure relates to a novel class of substituted quinoxaline derivatives. The disclosure further relates to pharmaceutical compositions containing such compounds and to the use of such compounds and compositions as anti-anaerobic agents.

Substituted pyrimidoquinoxalines useful as anti-anaerobic agents

This disclosure relates to a novel class of substituted dihydroimidazo[1,2-a]quinoxaline derivatives. The disclosure further relates to pharmaceutical compositions containing such compounds and to the use of such compounds and compositions as anti-anaerobic agents.

Substituted dihydroimidazo[1,2-a]quinoxalines

A series of novel 4-piperidino-6,7-dimethoxyquinazoline compounds, further substituted on the piperidino group, and the pharmaceutically-acceptable salts thereof, possess cardiac stimulating activity in mammals. They are useful in the curative or prophylactic treatment of cardiac conditions, in particular heart failure.

Growing community of inventors

Marlow, United Kingdom

Albert A Jaxa-Chamiec